Population pharmacokinetics and exposure–response modelling of firsekibart (GenSci048) in patients with acute gout flare: Implications for fixed‐dose optimization
British Journal of Clinical Pharmacology · 2026
DOI: 10.1002/bcp.70607 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Kun Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Qiangshi Information Technology Co., Ltd., Shanghai, China. Hauptthemen laut MEDLINE: Gout, Models, Biological, Antibodies, Monoclonal, Humanized, Gout Suppressants. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background and Objectives Firsekibart (formerly GenSci048 or genakumab) is a humanized anti‐IL‐1β monoclonal antibody developed for acute gouty flares in patients unsuitable for standard therapies. This study characterized its population pharmacokinetics (PopPK), assessing covariate effects, and established exposure–response (E‐R) relationships to guide dosing.
Methods
Data from four clinical trials involving 296 subjects (2287 concentrations) were pooled to develop a PopPK model using NONMEM with stepwise covariate screening. A one‐compartment model with sequential zero‐ and first‐order absorption was utilized. E‐R analyses were conducted to assess efficacy (dVAS 72h , defined as achieving ≥50% reduction in Visual Analog Scale [VAS] scores from baseline measured at 72 h) and safety (dyslipidaemia/hepatic dysfunction/infectious and invasive diseases) using logistic regression.
Results
Body weight significantly affected clearance and distribution volume. Hepatic or renal impairment caused exposure differences of less than 27%. No exposure‐dependent safety trends were identified across the evaluated exposure range. Although exposure–response trends were observed across the broader dose range, the gradient within the exposure range achieved by 195–200 mg was shallow, consistent with a plateau. Simulations indicated that at the 200‐mg dose, more than 95% of patients attained exposures associated with at least 85% probability of achieving dVAS 72h . Firsekibart also markedly reduced flare recurrence over 12 weeks compared with the control group.
Conclusion
Firsekibart demonstrated predictable pharmacokinetics, a favourable safety profile, and robust efficacy coverage at the 200‐mg fixed dose. These findings support fixed‐dosing for patients with acute gout flares who are intolerant of, unsuitable for, or inadequately responsive to standard‐of‐care therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Qiangshi Information Technology Co., Ltd., Shanghai, China.
- Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, China.
ORCID-Profile: Kun Wang
Zitieren
APA
Wang, K., Yang, J., Xu, F., Liu, L., Luo, T., Xu, Q., Gao, W., Ma, G., Fu, Y., & Zhu, X. (2026). Population pharmacokinetics and exposure–response modelling of firsekibart (GenSci048) in patients with acute gout flare: Implications for fixed‐dose optimization. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70607
Vancouver
Wang K, Yang J, Xu F, Liu L, Luo T, Xu Q, et al. Population pharmacokinetics and exposure–response modelling of firsekibart (GenSci048) in patients with acute gout flare: Implications for fixed‐dose optimization. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70607
BibTeX
@article{Wang2026,
author = {Wang, Kun and Yang, Juan and Xu, Fengyan and Liu, Lu and Luo, Tianhong and Xu, Qian and Gao, Weiwei and Ma, Guangli and Fu, Yongchao and Zhu, Xiaoyan},
title = {Population pharmacokinetics and exposure–response modelling of firsekibart (GenSci048) in patients with acute gout flare: Implications for fixed‐dose optimization},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70607}
}
EUVIMED